News | June 17, 2026
Indian pharma market logs sixth straight month of double-digit growth in May
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
A one-shot gene-editing cholesterol therapy could soon be a reality
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Subscribe To Our Newsletter & Stay Updated
